Mitral valve surgery in non-ischemic cardiomyopathy

D. L. Ngaage, Hartzell V Schaff

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Dilated cardiomyopathy is a disorder of the cardiac muscle in which myocyte cytoskeletal weakness leads to venatricular dilatation and congestive cardiac failure. Most commonly, the etiology of non-ischemic cardiomyopathy is unknowwn (idiopathic) and, in our practice, the second most common cause is advanced valvular heart disease. Functional mitral valve regurgitation occurs in up to 40% of patients with heart failure due to dilated cardiomyopathy and contributes to a vicious cycle of volume overload, further left ventricular dilatation, and worsening mitral valve regurgitation and heart failure. Surgical management of mitral valve regurgitation in dilated cardiomyopathy may carry a high risk and can be very challenging. However, operative risk is mitigated by continued vigorous medical management and judicious perioperative care. For example, at our Clinic, mortality, for mitral valve repair or replacement in 43 patients with non-ischemic cardiomyopathy having operation between 1993 and 2002 was 2.3%. Additional procedures to reverse cardiac remodeling have not proven to be uniformly successful and continue to undergo scientific serutiny. Clinical outcome of mitral valve surgery in non-ischemic dilated cardiomyopathy compares well with cardiac transplantation in the early-to-intermediate term, but the long-term results are less satisfactory. For our patients having mitral valve repair, the 1-, 3-, and 5-year survivorships, were 84% 80% and 33%. Evolving technology and research that focus on methods of altering or reversing cardiomyopathy; e.g., cell transplant, may have significant impact on the future management of this debilitating illness.

Original languageEnglish (US)
Pages (from-to)477-486
Number of pages10
JournalJournal of Cardiovascular Surgery
Volume45
Issue number5
StatePublished - Oct 2004

Fingerprint

Dilated Cardiomyopathy
Cardiomyopathies
Mitral Valve
Mitral Valve Insufficiency
Heart Failure
Dilatation
Perioperative Care
Heart Valve Diseases
Heart Transplantation
Muscle Cells
Myocardium
Survival Rate
Technology
Transplants
Mortality
Research

Keywords

  • Heart valve diseases
  • Mitral valve, surgery
  • Myocardial diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mitral valve surgery in non-ischemic cardiomyopathy. / Ngaage, D. L.; Schaff, Hartzell V.

In: Journal of Cardiovascular Surgery, Vol. 45, No. 5, 10.2004, p. 477-486.

Research output: Contribution to journalArticle

@article{9def9645597845d090711508e382341f,
title = "Mitral valve surgery in non-ischemic cardiomyopathy",
abstract = "Dilated cardiomyopathy is a disorder of the cardiac muscle in which myocyte cytoskeletal weakness leads to venatricular dilatation and congestive cardiac failure. Most commonly, the etiology of non-ischemic cardiomyopathy is unknowwn (idiopathic) and, in our practice, the second most common cause is advanced valvular heart disease. Functional mitral valve regurgitation occurs in up to 40{\%} of patients with heart failure due to dilated cardiomyopathy and contributes to a vicious cycle of volume overload, further left ventricular dilatation, and worsening mitral valve regurgitation and heart failure. Surgical management of mitral valve regurgitation in dilated cardiomyopathy may carry a high risk and can be very challenging. However, operative risk is mitigated by continued vigorous medical management and judicious perioperative care. For example, at our Clinic, mortality, for mitral valve repair or replacement in 43 patients with non-ischemic cardiomyopathy having operation between 1993 and 2002 was 2.3{\%}. Additional procedures to reverse cardiac remodeling have not proven to be uniformly successful and continue to undergo scientific serutiny. Clinical outcome of mitral valve surgery in non-ischemic dilated cardiomyopathy compares well with cardiac transplantation in the early-to-intermediate term, but the long-term results are less satisfactory. For our patients having mitral valve repair, the 1-, 3-, and 5-year survivorships, were 84{\%} 80{\%} and 33{\%}. Evolving technology and research that focus on methods of altering or reversing cardiomyopathy; e.g., cell transplant, may have significant impact on the future management of this debilitating illness.",
keywords = "Heart valve diseases, Mitral valve, surgery, Myocardial diseases",
author = "Ngaage, {D. L.} and Schaff, {Hartzell V}",
year = "2004",
month = "10",
language = "English (US)",
volume = "45",
pages = "477--486",
journal = "Journal of Cardiovascular Surgery",
issn = "0021-9509",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Mitral valve surgery in non-ischemic cardiomyopathy

AU - Ngaage, D. L.

AU - Schaff, Hartzell V

PY - 2004/10

Y1 - 2004/10

N2 - Dilated cardiomyopathy is a disorder of the cardiac muscle in which myocyte cytoskeletal weakness leads to venatricular dilatation and congestive cardiac failure. Most commonly, the etiology of non-ischemic cardiomyopathy is unknowwn (idiopathic) and, in our practice, the second most common cause is advanced valvular heart disease. Functional mitral valve regurgitation occurs in up to 40% of patients with heart failure due to dilated cardiomyopathy and contributes to a vicious cycle of volume overload, further left ventricular dilatation, and worsening mitral valve regurgitation and heart failure. Surgical management of mitral valve regurgitation in dilated cardiomyopathy may carry a high risk and can be very challenging. However, operative risk is mitigated by continued vigorous medical management and judicious perioperative care. For example, at our Clinic, mortality, for mitral valve repair or replacement in 43 patients with non-ischemic cardiomyopathy having operation between 1993 and 2002 was 2.3%. Additional procedures to reverse cardiac remodeling have not proven to be uniformly successful and continue to undergo scientific serutiny. Clinical outcome of mitral valve surgery in non-ischemic dilated cardiomyopathy compares well with cardiac transplantation in the early-to-intermediate term, but the long-term results are less satisfactory. For our patients having mitral valve repair, the 1-, 3-, and 5-year survivorships, were 84% 80% and 33%. Evolving technology and research that focus on methods of altering or reversing cardiomyopathy; e.g., cell transplant, may have significant impact on the future management of this debilitating illness.

AB - Dilated cardiomyopathy is a disorder of the cardiac muscle in which myocyte cytoskeletal weakness leads to venatricular dilatation and congestive cardiac failure. Most commonly, the etiology of non-ischemic cardiomyopathy is unknowwn (idiopathic) and, in our practice, the second most common cause is advanced valvular heart disease. Functional mitral valve regurgitation occurs in up to 40% of patients with heart failure due to dilated cardiomyopathy and contributes to a vicious cycle of volume overload, further left ventricular dilatation, and worsening mitral valve regurgitation and heart failure. Surgical management of mitral valve regurgitation in dilated cardiomyopathy may carry a high risk and can be very challenging. However, operative risk is mitigated by continued vigorous medical management and judicious perioperative care. For example, at our Clinic, mortality, for mitral valve repair or replacement in 43 patients with non-ischemic cardiomyopathy having operation between 1993 and 2002 was 2.3%. Additional procedures to reverse cardiac remodeling have not proven to be uniformly successful and continue to undergo scientific serutiny. Clinical outcome of mitral valve surgery in non-ischemic dilated cardiomyopathy compares well with cardiac transplantation in the early-to-intermediate term, but the long-term results are less satisfactory. For our patients having mitral valve repair, the 1-, 3-, and 5-year survivorships, were 84% 80% and 33%. Evolving technology and research that focus on methods of altering or reversing cardiomyopathy; e.g., cell transplant, may have significant impact on the future management of this debilitating illness.

KW - Heart valve diseases

KW - Mitral valve, surgery

KW - Myocardial diseases

UR - http://www.scopus.com/inward/record.url?scp=11344278192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11344278192&partnerID=8YFLogxK

M3 - Article

C2 - 15736570

AN - SCOPUS:11344278192

VL - 45

SP - 477

EP - 486

JO - Journal of Cardiovascular Surgery

JF - Journal of Cardiovascular Surgery

SN - 0021-9509

IS - 5

ER -